Masitinib for the treatment of locally advanced or metastatic pancreatic cancer
Following on from information provided to NICE by the company in November 2011, the appraisal of Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [566] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 566
Topic area
  • Cancer
  • Digestive system

Provisional Schedule

Closing date for invited submissions / evidence submission: 12 November 2013
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Communications manager: Alice Law
Project manager:

Bijal Joshi
Technical Lead: Rosemary Lovett

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Following on from information provided to NICE by the company in November 2011, the appraisal of Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [566] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022 Discontinued. Following on from information provided to NICE by the company in November 2011, the appraisal of Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [566] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
10 July 2014

On 24 Jan 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for masitinib. Following a re-examination of the opinion, at the request of the applicant, a further refusal of the marketing authorisation was given on 27 May 2014.

Therefore, the appraisal of masitinib for treating locally advanced or metastatic pancreatic cancer [ID566] has been suspended indefinitely on the technology appraisals work programme.
04 February 2014

Please note that the manufacturer has informed NICE that they will not provide an evidence submission on the date requested, therefore we are temporarily suspending the appraisal whilst we consider the next steps.

Therefore, the Committee Meeting will note take place 23 April 2014
03 May 2013 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.

For further information on our processes and methods, please see our CHTE processes and methods manual